Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the chlamydia market size evolved in recent years?

The market for chlamydia has seen substantial growth in the past years. The statistics predict a surge in its market size from $2.97 billion in 2024 to $3.23 billion in 2025, marking a Compound Annual Growth Rate (CAGR) of 9.1%. Factors contributing to this increase in the historic period consist of a higher reach of sexual health education programs, escalating demand for quick diagnostic tests, a greater requirement for cost-effective and scalable STI diagnostics, expansion in telemedicine, and intensified focus on precision medicine.

What are the predictions for the chlamydia market size in the coming years?

In the coming years, robust growth is anticipated in the chlamydia market. By 2029, it is predicted to expand to $4.53 billion with a Compound Annual Growth Rate (CAGR) of 8.8%. Factors such as the rising incidence of chlamydia, heightened public awareness, an increase in point-of-care testing solutions, a growing prevalence of sexually transmitted infections, and enhanced investment in research and development contribute to this growth for the forecasted period. Key trends in the forecast period encompass a shift to point-of-care testing, advancements in molecular diagnostics, a move towards preventative healthcare, the application of artificial intelligence in diagnostics, and the creation of high-throughput screening platforms.

Get your chlamydia market report here!

https://www.thebusinessresearchcompany.com/report/chlamydia-global-market-report

What key factors are fueling the growth of the chlamydia market?

The chlamydia market is predicted to surge due to the rising rate of sexually transmitted diseases (STDs). STDs, such as chlamydia, gonorrhea, and HIV, are infections transferred through sexual intercourse. A surge in STDs is linked to decreased usage of condoms, inadequate awareness, limited healthcare access, and increased use of dating apps encouraging multiple sexual partners. Treatment for chlamydia assists in curtailing the spread of STDs by treating the infection, preventing further complications and decreasing the risk of transmitting the disease to sexual partners. The National Association of County and City Health officials, a US nonprofit organization, reported over 2.5 million instances of syphilis, gonorrhea, and chlamydia in the U.S. in June 2024, with an 80% increase in syphilis and a shocking rise of 937% in congenital syphilis cases. The recorded congenital syphilis cases were 3,755, highlighting a 31% increase from 2021 to 2022. Therefore, the escalating occurrence of sexually transmitted diseases is contributing to the chlamydia market growth. Simultaneously, the growth of the chlamydia market is also expected to be fueled by the proliferation of telemedicine services. Telemedicine is the provision of healthcare services remotely using digital communication technologies, such as mobile applications, video calls, and remote monitoring instruments. This proliferation is credited to digital health technology advancements, more widespread high-speed internet accessibility, and rising demand for remote healthcare choices. Telemedicine enhances chlamydia management by providing remote consultations, secure prescription services, and confidential follow-up care, promoting convenience and timely treatment adherence. US Based non-profit organization, FAIR Health Inc. reported a national increase in telehealth usage by 7.3% in April 2023, rising from 5.5% of medical claim lines in December 2022 to 5.9% in January 2023. Further, Rock Health, a US venture capital firm, reported in February 2023 that according to their 2022 survey, 80% of respondents had previously utilized telemedicine, displaying an 8-percentage-point uptick from 72% in 2021. Consequently, the expansion of telemedicine services is boosting the growth of the chlamydia market.

How is the global chlamydia market divided into key segments?

The chlamydia market covered in this report is segmented –

1) By Test Type: Culture Tests, Nucleic Acid Amplification Test (NAAT), Direct Fluorescent Antibody Test, Serology Tests, Other Test Types

2) By Route Of Administration: Oral, Injectable, Other Routes Of Administration

3) By End User: Hospitals, Diagnostic Centers, Ambulatory Surgical Centers, Other End Users

Subsegments:

1) By Culture Tests: Urethral Swab Culture, Endocervical Swab Culture, Urine Culture Test, Conjunctival Swab Culture

2) By Nucleic Acid Amplification Test (NAAT): PCR (Polymerase Chain Reaction), Transcription-Mediated Amplification (TMA), Strand Displacement Amplification (SDA), Loop-Mediated Isothermal Amplification (LAMP)

3) By Direct Fluorescent Antibody Test: DFA Test For Urogenital Chlamydia, DFA Test For Ocular Chlamydia, DFA For Respiratory Chlamydia Detection

4) By Serology Tests: Enzyme-Linked Immunosorbent Assay (ELISA), Immunofluorescence Assay (IFA), Western Blot

5) By Other Test Types: Immunochromatographic Rapid Test, Lateral Flow Immunoassay, Hybrid Capture Test (HCT)

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21138&type=smp

Who are the key firms paving the way for growth in the chlamydia market?

Major companies operating in the chlamydia market are Pfizer Inc., Siemens Healthineers, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Thermo Fisher Scientific Inc., AstraZeneca, Abbott Laboratories, GlaxoSmithKline Plc, Gilead Sciences Inc., Danaher Corporation, Becton, Dickinson and Company, Hologic Inc., Quidel Corporation, Bio-Rad Laboratories Inc., Ortho Clinical Diagnostics, DiaSorin SpA, Eiken Chemical Co. Ltd., MedMira Inc., GenMark Diagnostics Inc., Aytu BioScience Inc., ACON Laboratories, Inc., Biocartis Group NV, Inova Diagnostics Inc., Trinity Biotech Plc, Laxai Pharma Ltd.

What key trends are currently impacting the chlamydia market’s development?

Leading corporations within the chlamydia market are prioritizing the creation of fully automated devices to boost diagnostic precision, decrease human mistakes, and amplify testing effectiveness. A fully automated tool refers to a gadget or system designed to undertake tasks without the need for human involvement, typically deploying sensors, control systems, and artificial intelligence to execute its duties autonomously. To illustrate, in May 2022, BD (Becton, Dickinson and Company), an American medical device firm, introduced the BD COR MX/PX System. The first test available on this fresh system is the BD CTGCTV2 molecular assay. This singular test can identify the three most prevalent non-viral sexually transmitted infections (STIs) – chlamydia trachomatis (CT), neisseria gonorrhoeae (GC), and trichomonas vaginalis (TV). These STIs potentially result in numerous negative health consequences for patients, such as complications with pregnancy and a heightened likelihood of contracting HIV.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21138

What regions are contributing significantly to the growth of the chlamydia market?

North America was the largest region in the chlamydia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chlamydia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Complicated Skin And Skin Structure Infections Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/complicated-skin-and-skin-structure-infections-drugs-global-market-report

Skin Booster Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/skin-booster-global-market-report

Allergy Conjunctivitis Global Market Report 2025

https://thebusinessresearchcompany.com/report/allergy-conjunctivitis-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: